KR20210112316A - 치료제로서의 cgas 활성 억제제 - Google Patents

치료제로서의 cgas 활성 억제제 Download PDF

Info

Publication number
KR20210112316A
KR20210112316A KR1020217020729A KR20217020729A KR20210112316A KR 20210112316 A KR20210112316 A KR 20210112316A KR 1020217020729 A KR1020217020729 A KR 1020217020729A KR 20217020729 A KR20217020729 A KR 20217020729A KR 20210112316 A KR20210112316 A KR 20210112316A
Authority
KR
South Korea
Prior art keywords
pyrimidin
methylbenzofuro
carboxylic acid
pyrrolidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217020729A
Other languages
English (en)
Korean (ko)
Inventor
로버트 지. 로어리
미라 쿠마르
매튜 복서
데이비드 말로니
수잔 보이드
Original Assignee
벨부르크 랩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벨부르크 랩스, 엘엘씨 filed Critical 벨부르크 랩스, 엘엘씨
Publication of KR20210112316A publication Critical patent/KR20210112316A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217020729A 2019-01-04 2020-01-03 치료제로서의 cgas 활성 억제제 Withdrawn KR20210112316A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788624P 2019-01-04 2019-01-04
US62/788,624 2019-01-04
PCT/US2020/012243 WO2020142729A1 (en) 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents

Publications (1)

Publication Number Publication Date
KR20210112316A true KR20210112316A (ko) 2021-09-14

Family

ID=72338800

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020729A Withdrawn KR20210112316A (ko) 2019-01-04 2020-01-03 치료제로서의 cgas 활성 억제제

Country Status (8)

Country Link
US (1) US20220073532A1 (https=)
EP (1) EP3906241A4 (https=)
JP (1) JP7507161B2 (https=)
KR (1) KR20210112316A (https=)
CN (1) CN113302194A (https=)
AU (1) AU2020205114A1 (https=)
CA (1) CA3125625A1 (https=)
WO (1) WO2020142729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021349249A1 (en) * 2020-09-24 2023-04-13 Ventus Therapeutics U.S., Inc. Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals
US20240174684A1 (en) * 2021-02-11 2024-05-30 Bellbrook Labs, Llc INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
CN117337291A (zh) * 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有C-连接环状取代基的吡啶衍生物
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025172882A1 (en) 2024-02-14 2025-08-21 Janssen Pharmaceutica Nv Substituted pyrrolidine-2-carboxylic acid derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP1812113A1 (en) * 2004-11-11 2007-08-01 Argenta Discovery Limited Pyrimidine compounds as histamine modulators
EP1767537A1 (en) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
KR20250065420A (ko) * 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치
WO2019084271A1 (en) * 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
US20220073532A1 (en) 2022-03-10
EP3906241A1 (en) 2021-11-10
EP3906241A4 (en) 2022-11-02
AU2020205114A1 (en) 2021-07-22
WO2020142729A1 (en) 2020-07-09
JP2022518148A (ja) 2022-03-14
CA3125625A1 (en) 2020-07-09
JP7507161B2 (ja) 2024-06-27
CN113302194A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
KR20210112316A (ko) 치료제로서의 cgas 활성 억제제
KR101442585B1 (ko) 특정 치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
JP7507162B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
JP5940148B2 (ja) 新規Ｓｙｋ阻害剤としての置換ピリドピラジン
TW202016094A (zh) 週期素依賴性激酶抑制劑
EA036788B1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN101605778A (zh) 某些取代的酰胺、其制备方法及使用方法
US20240174684A1 (en) INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
TW201038554A (en) Nicotinamide derivatives, their preparation and their therapeutic application
JP2019501919A (ja) スルファミド誘導体およびその製造方法と応用
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
TW202448435A (zh) 經取代之噻二唑基化合物
CN111909133B (zh) 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺
CN113166148B (zh) 作为cdk-hdac双通路抑制剂的杂环化合物
JP2022548230A (ja) 新規化合物及び方法
CN111212644B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
KR20150091168A (ko) 피리돈 화합물
JP2025528113A (ja) 治療剤としてのｃＧＡＳ活性の阻害剤
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
HK40032523B (en) Substituted 1-amino-1h-imidazole-5-carboxamides as brunauer tyrosine kinase inhibitors
CN111225669A (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221227

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240814

WITB Written withdrawal of application